

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR® Depot) for Symptomatic Ascites in Cancer Patients

Status Change – August 7, 2009

NOTICE OF STATUS CHANGE

This study is permanently closed to patient accrual effective Friday, August 7, 2009. Patient entry will not be allowed after 4:30 p.m. CST, Thursday, August 6, 2009.

The study is closed due to slow accrual. Patients currently on study should be followed according to the protocol.

Please retain this notice with the protocol.